Sandbox Reserved 1176

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 28: Line 28:
===Active State===
===Active State===
-
After determining the original structural state, <scene name='72/721547/Ntsr1-gw5/8'>NTSR1-GW5</scene>, as only active-like, the structure of NTSR1 was determined in an active state.<ref name="SPGP"/> By reverting back three of the original six mutations from the active-like structure on the basis of their location, NTSR1 gained near wild-type activity.<ref name="SPGP"/> The three reversions were Asp166, Leu310, and Phe358, and this protein was named <scene name='72/721548/Ntsr1-elf/6'>NTSR1-ELF</scene>. The revival of activity in NTSR1 indicated that the reverted amino acid residues (Asp166, Leu310, and Phe358) play significant roles in G-protein activity.<ref name="SPGP"/>
+
After determining the original structural state, <scene name='72/721547/Ntsr1-gw5/8'>NTSR1-GW5</scene>, as only active-like, the structure of NTSR1 was determined in an active state.<ref name="SPGP"/> By reverting back three of the original six mutations from the active-like structure on the basis of their location<ref name="SPGP"/>, NTSR1 gained near wild-type activity.<ref name="SPGP"/> The three reversions were Asp166, Leu310, and Phe358, and this protein was named <scene name='72/721548/Ntsr1-elf/6'>NTSR1-ELF</scene>. The revival of activity in NTSR1 indicated that the reverted amino acid residues (Asp166, Leu310, and Phe358) play significant roles in G-protein activity.<ref name="SPGP"/>
====Leu310====
====Leu310====

Revision as of 01:25, 22 April 2016

An interactive view of the class A GPCR, NTSR1 (blue). This protein gets its activity from binding to the 13 amino acid ligand, NTS (red).

Drag the structure with the mouse to rotate

References

  1. 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 1.13 1.14 1.15 1.16 1.17 1.18 1.19 1.20 1.21 Krumm BE, White JF, Shah P, Grisshammer R. Structural prerequisites for G-protein activation by the neurotensin receptor. Nat Commun. 2015 Jul 24;6:7895. doi: 10.1038/ncomms8895. PMID:26205105 doi:http://dx.doi.org/10.1038/ncomms8895
  2. 2.0 2.1 2.2 2.3 2.4 2.5 2.6 2.7 White JF, Noinaj N, Shibata Y, Love J, Kloss B, Xu F, Gvozdenovic-Jeremic J, Shah P, Shiloach J, Tate CG, Grisshammer R. Structure of the agonist-bound neurotensin receptor. Nature. 2012 Oct 25;490(7421):508-13. doi: 10.1038/nature11558. Epub 2012 Oct 10. PMID:23051748 doi:http://dx.doi.org/10.1038/nature11558
  3. 3.0 3.1 3.2 3.3 Liang Y, Boules M, Li Z, Williams K, Miura T, Oliveros A, Richelson E. Hyperactivity of the dopaminergic system in NTS1 and NTS2 null mice. Neuropharmacology. 2010 Jun;58(8):1199-205. doi:, 10.1016/j.neuropharm.2010.02.015. Epub 2010 Mar 6. PMID:20211191 doi:http://dx.doi.org/10.1016/j.neuropharm.2010.02.015
  4. 4.0 4.1 4.2 Carraway RE, Plona AM. Involvement of neurotensin in cancer growth: evidence, mechanisms and development of diagnostic tools. Peptides. 2006 Oct;27(10):2445-60. Epub 2006 Aug 2. PMID:16887236 doi:http://dx.doi.org/10.1016/j.peptides.2006.04.030
  5. 5.0 5.1 5.2 Griebel G, Holsboer F. Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning? Nat Rev Drug Discov. 2012 May 18;11(6):462-78. doi: 10.1038/nrd3702. PMID:22596253 doi:http://dx.doi.org/10.1038/nrd3702
Personal tools